Top 10 Pharmaceutical Revenue KPIs

Curated by Kory White · Fractional CRO, CRO Syndicate

👍 Yup or 👎 Nope — vote this up its category:

📅 Published Jun 26, 2026 · Updated Jun 26, 2026 · 9 min read

Direct Answer

For pharmaceutical revenue operations, Net Revenue per Prescription (NRx) is the #1 best overall KPI because it directly ties commercial activity to actual cash flow, net of rebates and discounts. The runner-up is Total Prescription Volume (TRx), which remains essential for market-share analysis and sales-force sizing.

This ranking is built for RevOps leaders, commercial analytics directors, and FP&A teams who need to audit their metric stack against industry benchmarks from IQVIA, ZS Associates, and Veeva.

How We Ranked These

We evaluated each KPI against five criteria: actionability (can a team change the number this quarter?), revenue correlation (how directly does it map to P&L line items?), benchmark availability (are there external norms from IQVIA/Symphony?), tool support (is it a standard object in Salesforce Health Cloud or Veeva CRM?), and complexity cost (how much data engineering is required to produce it reliably).

Each KPI received a composite score out of 100; the ranking reflects those scores, with tiebreakers favoring metrics that are auditable by external auditors (e.g., for SEC reporting).

1. Net Revenue per Prescription (NRx) 🏆 BEST OVERALL

Net Revenue per Prescription (NRx) is the after-rebate, after-discount revenue a manufacturer realizes for each dispensed script. It is the single most important metric because it captures the real cash flow from commercial activity, net of the gross-to-net (GTN) adjustments that can erase 40–60% of list price in some therapeutic categories (e.g., insulin, GLP-1s).

Without NRx, a team celebrating high TRx volume may be bleeding margin.

Use NRx to evaluate contract performance with PBMs and GPOs. A drop in NRx often signals that a PBM has shifted a brand to a less favorable formulary tier, or that a new chargeback agreement has kicked in. Pair NRx with Gross Sales in a Veeva CRM dashboard to create a GTN waterfall.

For example, if Gross Sales are $100M and NRx is $55M, the GTN gap is 45% — a red flag for the finance committee. Tools like Model N and Revitas (now part of Accruent) automate NRx calculation from contract terms, but you should still validate monthly against the IQVIA National Sales Perspectives file.

2. Total Prescription Volume (TRx)

Total Prescription Volume (TRx) counts all dispensed prescriptions for a product, including new and refill scripts, across all channels. It is the foundational volume metric used by IQVIA in its monthly market-share reports. TRx is less sensitive to pricing noise than NRx, making it the preferred metric for sales-force sizing and territory alignment in Salesforce.

Use TRx to benchmark against competitors in the same Anatomical Therapeutic Chemical (ATC) class. If your TRx is flat while the class grows 8%, your share is eroding. The Clari revenue platform can ingest weekly TRx data from IQVIA and alert reps when a territory falls below the 20th percentile.

However, TRx alone can mislead: a product with high TRx but low NRx may be unprofitable. Always view TRx alongside a pricing waterfall.

3. New-to-Brand Prescription Volume (NBRx)

New-to-Brand Prescription Volume (NBRx) counts only first-time prescriptions for a specific brand, excluding refills and switches from other brands. It is the leading indicator of market adoption and is especially critical during a product launch. NBRx data is available from Symphony Health (an IQVIA company) with a 7-day lag.

Use NBRx to measure the effectiveness of DTC campaigns and key opinion leader (KOL) seeding programs. A common benchmark: a successful launch should see NBRx grow 15–25% month-over-month for the first six months. In Salesforce Health Cloud, you can create an NBRx trend line for each territory and overlay rep call activity.

If NBRx stalls while TRx climbs, your product is gaining refills but not new patients — a classic sign of a mature market or a payer access barrier.

4. Gross-to-Net (GTN) Percentage

Gross-to-Net (GTN) Percentage measures the total reduction from list price to net revenue, expressed as a percentage. It aggregates all rebates, chargebacks, discounts, copay assistance, and Medicaid 340B adjustments. For most branded pharmaceuticals, GTN ranges from 40% to 65%, with high-competition classes (e.g., TNF inhibitors) at the top end.

Track GTN monthly in a Veeva Vault PromoMats dashboard that pulls contract data from Model N. A sudden GTN spike of 3–5 percentage points usually indicates a new PBM contract with steeper rebates or a Medicaid best-price recalculation. The SEC requires quarterly GTN disclosure in 10-K filings for material products.

If your GTN exceeds 60%, your commercial model may be unsustainable — consider a price increase or a patient-access program redesign.

5. Sales Rep Call-to-Prescription Conversion Rate

This KPI measures the percentage of physician calls by a sales rep that result in a new prescription within 30 days. It is the classic return on selling effort metric. Industry averages vary by specialty: primary care reps see 2–4% conversion, while specialty reps (e.g., oncology) may see 8–12% due to smaller, more targeted call lists.

Use the Challenger Sale framework to segment physicians by repurchase propensity and brand loyalty. In Salesforce, create a report that joins call records (from Veeva CRM) with prescription data (from IQVIA). If conversion drops below 2% for a territory, investigate whether the rep is calling on the right physicians or if a payer restriction has changed.

Tools like Gong can analyze call recordings to identify language patterns that correlate with higher conversion.

6. Patient Adherence Rate (Proportion of Days Covered)

Patient Adherence Rate, measured as Proportion of Days Covered (PDC), indicates how consistently patients take a medication over a 12-month period. For chronic conditions (diabetes, hypertension, cholesterol), PDC below 80% is considered non-adherent. Poor adherence directly reduces repeat prescription volume and increases patient churn.

Use PDC data from pharmacy claims (available via IQVIA or Symphony Health) to identify high-risk patient segments. In Salesforce, you can create a patient adherence score that triggers a copay card renewal reminder or a nurse educator call. A 5-point improvement in PDC can increase annual NRx by 10–15% for a mature brand.

The Centers for Medicare & Medicaid Services (CMS) uses PDC in its Star Ratings for Part D plans, so it directly affects payer contract terms.

Market Share is your product’s prescription volume (or revenue) divided by the total for its therapeutic class. It is the ultimate competitive benchmark. IQVIA publishes monthly market-share data by ATC level 4 (e.g., “statins” vs. “atorvastatin”). A share gain of 1% in a $10B market is worth $100M in gross sales.

Use market share to evaluate launch success and competitive response. In Winning by Design frameworks, share is a lagging indicator of product differentiation and sales execution. A common target: achieve 20% share within 12 months of launch for a first-in-class drug.

Track share weekly using IQVIA’s weekly Rx data and overlay it with PBM formulary status in a Power BI dashboard. If share drops 2% in one month, investigate whether a competitor launched a new indication or a PBM moved your product to a non-preferred tier.

8. Customer Acquisition Cost (CAC) per New Prescriber

CAC per New Prescriber divides total commercial spend (sales rep salaries, DTC advertising, medical education) by the number of new physicians who wrote at least one prescription for your brand in a quarter. This is a unit economics metric borrowed from SaaS but adapted for pharma.

A reasonable range for primary care is $5,000–$15,000 per new prescriber; for specialty drugs, it can exceed $50,000 due to smaller target lists and higher rep costs. Use Salesforce to track prescriber-level CAC by territory. If CAC exceeds $20,000 in a territory, consider reallocating rep time to higher-potential physicians.

The MEDDIC framework can help qualify which prescribers are worth the investment: prioritize those with high patient volume and low brand loyalty to competitors.

9. Revenue per Rep (RPR)

Revenue per Rep (RPR) is the annual net revenue attributed to a single sales representative’s territory. It is a direct measure of sales-force productivity. For a typical brand, RPR ranges from $2M to $8M per rep, depending on therapy area and territory density.

Salesloft and Outreach can track rep activities (calls, emails, meetings) and correlate them with territory revenue.

Use RPR to right-size your sales force. If a rep’s RPR is below $1M, that territory may be over-serviced or under-populated with high-prescribing physicians. A territory alignment project in Salesforce can rebalance accounts to improve RPR by 10–15%.

The Gartner sales force effectiveness benchmarks suggest that a 10% improvement in RPR can boost overall brand profitability by 3–5%.

10. Prescriber Loyalty Index (PLI) 💎 BEST VALUE

Prescriber Loyalty Index (PLI) measures the percentage of a physician’s total prescriptions in a class that go to your brand. It is a share-of-wallet metric that costs almost nothing to compute if you already have IQVIA data. PLI is the best value KPI because it requires no new data sources — just a simple ratio of your brand’s scripts to the physician’s total scripts in the class.

Use PLI to segment prescribers into loyalists (PLI > 50%), switchers (PLI 20–50%), and non-adopters (PLI < 20%). In Salesforce, create a report that flags prescribers whose PLI dropped by 10 points in a quarter — that’s a leading indicator of a competitive win or a payer restriction.

For a $500M brand, a 5% improvement in PLI among the top 1,000 prescribers can add $25M in annual revenue. PLI is also a key input for key account management (KAM) programs.

flowchart TD A[Start: Select Pharma Revenue KPI] --> B{Primary Goal?} B -->|Cash Flow Visibility| C[Use NRx] B -->|Volume Growth| D[Use TRx] B -->|New Patient Adoption| E[Use NBRx] B -->|Profitability Analysis| F[Use GTN%] B -->|Sales Force Efficiency| G[Use RPR] C --> H[Pair with GTN% for Waterfall] D --> I[Pair with Market Share] E --> J[Pair with CAC per Prescriber] F --> K[Monitor Monthly vs. Contract Terms] G --> L[Benchmark vs. Industry Average] H --> M[Quarterly Finance Review] I --> N[Competitive Response Plan] J --> O[Launch Optimization] K --> P[PBM Contract Renegotiation] L --> Q[Territory Realignment]

FAQ

What is the difference between NRx and TRx? NRx is net revenue per prescription (after rebates/discounts), while TRx is total prescription count. NRx measures cash flow; TRx measures volume. Both are needed for a complete picture.

How often should GTN% be calculated? Monthly, with a quarterly review against contract terms. A spike in GTN% often signals a PBM contract change or a Medicaid best-price adjustment.

Which KPI is best for a product launch? NBRx (new-to-brand prescriptions) is the leading indicator. Pair it with CAC per new prescriber to measure launch efficiency.

Can I use these KPIs in a Salesforce dashboard? Yes. All 10 can be built in Salesforce Health Cloud or Veeva CRM using custom report types and joined data from IQVIA or Symphony Health.

What is a healthy PLI score? For a market-leading brand, PLI above 50% among top prescribers is strong. For a challenger brand, 20–30% is acceptable in the first 12 months.

How do I benchmark RPR? IQVIA publishes annual sales force effectiveness benchmarks. A typical range is $2M–$8M per rep for primary care; specialty reps often exceed $10M.

What tool automates NRx calculation? Model N and Accruent Revitas automate NRx from contract terms. Veeva Vault PromoMats can centralize GTN data for reporting.

Is CAC per prescriber applicable to generics? Yes, but the range is much lower ($500–$2,000) due to lower margins and higher prescriber turnover.

How does PDC affect payer contracts? CMS uses PDC in Part D Star Ratings. A 5-point PDC improvement can lead to better formulary placement and higher NRx.

Which KPI is most auditable by external auditors? NRx and GTN% are directly tied to SEC 10-K disclosures and are audited by Big Four firms. TRx and NBRx are not typically audited.

Sources

Bottom Line

The top 10 pharmaceutical revenue KPIs — led by Net Revenue per Prescription (NRx) and anchored by Prescriber Loyalty Index (PLI) — form a complete commercial analytics stack for any RevOps team. Start with NRx and GTN% for financial accuracy, layer in TRx and NBRx for volume insights, and use RPR and PLI for sales-force optimization.

Implement these in Salesforce Health Cloud or Veeva CRM with data feeds from IQVIA and Model N to build a real-time revenue operations dashboard that supports both quarterly reporting and daily decision-making.

*pharmaceutical revenue KPIs, pharma RevOps metrics, net revenue per prescription, GTN percentage, pharma sales analytics*

Keep reading

![Top 10 Pharmaceutical Revenue KPIs](https://static.wixstatic.com/media/5c77bc_9e1341789d714c009b747ce8398f185b~mv2.png/v1/fill/w_980,h_735,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/5c77bc_9e1341789d714c009b747ce8398f185b~mv2.png)

### Direct Answer
For pharmaceutical revenue operations, **Net Revenue per Prescription (NRx)** is the #1 best overall KPI because it directly ties commercial activity to actual cash flow, net of rebates and discounts. The runner-up is **Total Prescription Volume (TRx)**, which remains essential for market-share analysis and sales-force sizing. This ranking is built for RevOps leaders, commercial analytics directors, and FP&A teams who need to audit their metric stack against industry benchmarks from IQVIA, ZS Associates, and Veeva.

## How We Ranked These
We evaluated each KPI against five criteria: **actionability** (can a team change the number this quarter?), **revenue correlation** (how directly does it map to P&L line items?), **benchmark availability** (are there external norms from IQVIA/Symphony?), **tool support** (is it a standard object in Salesforce Health Cloud or Veeva CRM?), and **complexity cost** (how much data engineering is required to produce it reliably). Each KPI received a composite score out of 100; the ranking reflects those scores, with tiebreakers favoring metrics that are auditable by external auditors (e.g., for SEC reporting).

## 1. Net Revenue per Prescription (NRx) 🏆 BEST OVERALL
**Net Revenue per Prescription (NRx)** is the after-rebate, after-discount revenue a manufacturer realizes for each dispensed script. It is the single most important metric because it captures the real cash flow from commercial activity, net of the **gross-to-net (GTN)** adjustments that can erase 40–60% of list price in some therapeutic categories (e.g., insulin, GLP-1s). Without NRx, a team celebrating high TRx volume may be bleeding margin.

Use NRx to evaluate **contract performance** with PBMs and GPOs. A drop in NRx often signals that a PBM has shifted a brand to a less favorable formulary tier, or that a new **chargeback** agreement has kicked in. Pair NRx with **Gross Sales** in a Veeva CRM dashboard to create a GTN waterfall. For example, if Gross Sales are $100M and NRx is $55M, the GTN gap is 45% — a red flag for the finance committee. Tools like **Model N** and **Revitas** (now part of Accruent) automate NRx calculation from contract terms, but you should still validate monthly against the **IQVIA National Sales Perspectives** file.

## 2. Total Prescription Volume (TRx)
**Total Prescription Volume (TRx)** counts all dispensed prescriptions for a product, including new and refill scripts, across all channels. It is the foundational volume metric used by **IQVIA** in its monthly market-share reports. TRx is less sensitive to pricing noise than NRx, making it the preferred metric for **sales-force sizing** and **territory alignment** in Salesforce.

Use TRx to benchmark against competitors in the same **Anatomical Therapeutic Chemical (ATC) class**. If your TRx is flat while the class grows 8%, your share is eroding. The **Clari** revenue platform can ingest weekly TRx data from IQVIA and alert reps when a territory falls below the 20th percentile. However, TRx alone can mislead: a product with high TRx but low NRx may be unprofitable. Always view TRx alongside a **pricing waterfall**.

## 3. New-to-Brand Prescription Volume (NBRx)
**New-to-Brand Prescription Volume (NBRx)** counts only first-time prescriptions for a specific brand, excluding refills and switches from other brands. It is the leading indicator of **market adoption** and is especially critical during a product launch. NBRx data is available from **Symphony Health** (an IQVIA company) with a 7-day lag.

Use NBRx to measure the effectiveness of **DTC campaigns** and **key opinion leader (KOL) seeding programs**. A common benchmark: a successful launch should see NBRx grow 15–25% month-over-month for the first six months. In **Salesforce Health Cloud**, you can create an NBRx trend line for each territory and overlay rep call activity. If NBRx stalls while TRx climbs, your product is gaining refills but not new patients — a classic sign of a **mature market** or a **payer access barrier**.

## 4. Gross-to-Net (GTN) Percentage
**Gross-to-Net (GTN) Percentage** measures the total reduction from list price to net revenue, expressed as a percentage. It aggregates all **rebates, chargebacks, discounts, copay assistance, and Medicaid 340B adjustments**. For most branded pharmaceuticals, GTN ranges from 40% to 65%, with high-competition classes (e.g., TNF inhibitors) at the top end.

Track GTN monthly in a **Veeva Vault PromoMats** dashboard that pulls contract data from **Model N**. A sudden GTN spike of 3–5 percentage points usually indicates a new **PBM contract** with steeper rebates or a **Medicaid best-price** recalculation. The **SEC** requires quarterly GTN disclosure in 10-K filings for material products. If your GTN exceeds 60%, your commercial model may be unsustainable — consider a **price increase** or a **patient-access program redesign**.

## 5. Sales Rep Call-to-Prescription Conversion Rate
This KPI measures the percentage of **physician calls** by a sales rep that result in a new prescription within 30 days. It is the classic **return on selling effort** metric. Industry averages vary by specialty: primary care reps see 2–4% conversion, while specialty reps (e.g., oncology) may see 8–12% due to smaller, more targeted call lists.

Use the **Challenger Sale** framework to segment physicians by **repurchase propensity** and **brand loyalty**. In **Salesforce**, create a report that joins call records (from **Veeva CRM**) with prescription data (from IQVIA). If conversion drops below 2% for a territory, investigate whether the rep is calling on the right physicians or if a **payer restriction** has changed. Tools like **Gong** can analyze call recordings to identify language patterns that correlate with higher conversion.

## 6. Patient Adherence Rate (Proportion of Days Covered)
**Patient Adherence Rate**, measured as **Proportion of Days Covered (PDC)**, indicates how consistently patients take a medication over a 12-month period. For chronic conditions (diabetes, hypertension, cholesterol), PDC below 80% is considered non-adherent. Poor adherence directly reduces **repeat prescription volume** and increases **patient churn**.

Use PDC data from **pharmacy claims** (available via IQVIA or **Symphony Health**) to identify high-risk patient segments. In **Salesforce**, you can create a **patient adherence score** that triggers a **copay card renewal** reminder or a **nurse educator call**. A 5-point improvement in PDC can increase annual NRx by 10–15% for a mature brand. The **Centers for Medicare & Medicaid Services (CMS)** uses PDC in its **Star Ratings** for Part D plans, so it directly affects payer contract terms.

## 7. Market Share (Volume or Value)
**Market Share** is your product’s prescription volume (or revenue) divided by the total for its **therapeutic class**. It is the ultimate competitive benchmark. IQVIA publishes monthly market-share data by **ATC level 4** (e.g., “statins” vs. “atorvastatin”). A share gain of 1% in a $10B market is worth $100M in gross sales.

Use market share to evaluate **launch success** and **competitive response**. In **Winning by Design** frameworks, share is a lagging indicator of **product differentiation** and **sales execution**. A common target: achieve 20% share within 12 months of launch for a first-in-class drug. Track share weekly using **IQVIA’s weekly Rx data** and overlay it with **PBM formulary status** in a **Power BI** dashboard. If share drops 2% in one month, investigate whether a competitor launched a new indication or a PBM moved your product to a non-preferred tier.

## 8. Customer Acquisition Cost (CAC) per New Prescriber
**CAC per New Prescriber** divides total commercial spend (sales rep salaries, DTC advertising, medical education) by the number of **new physicians** who wrote at least one prescription for your brand in a quarter. This is a **unit economics** metric borrowed from SaaS but adapted for pharma.

A reasonable range for primary care is $5,000–$15,000 per new prescriber; for specialty drugs, it can exceed $50,000 due to smaller target lists and higher rep costs. Use **Salesforce** to track prescriber-level CAC by territory. If CAC exceeds $20,000 in a territory, consider reallocating rep time to higher-potential physicians. The **MEDDIC** framework can help qualify which prescribers are worth the investment: prioritize those with **high patient volume** and **low brand loyalty** to competitors.

## 9. Revenue per Rep (RPR)
**Revenue per Rep (RPR)** is the annual net revenue attributed to a single sales representative’s territory. It is a direct measure of **sales-force productivity**. For a typical brand, RPR ranges from $2M to $8M per rep, depending on therapy area and territory density. **Salesloft** and **Outreach** can track rep activities (calls, emails, meetings) and correlate them with territory revenue.

Use RPR to **right-size** your sales force. If a rep’s RPR is below $1M, that territory may be over-serviced or under-populated with high-prescribing physicians. A **territory alignment** project in **Salesforce** can rebalance accounts to improve RPR by 10–15%. The **Gartner** sales force effectiveness benchmarks suggest that a 10% improvement in RPR can boost overall brand profitability by 3–5%.

## 10. Prescriber Loyalty Index (PLI) 💎 BEST VALUE
**Prescriber Loyalty Index (PLI)** measures the percentage of a physician’s total prescriptions in a class that go to your brand. It is a **share-of-wallet** metric that costs almost nothing to compute if you already have IQVIA data. PLI is the best value KPI because it requires no new data sources — just a simple ratio of your brand’s scripts to the physician’s total scripts in the class.

Use PLI to segment prescribers into **loyalists** (PLI > 50%), **switchers** (PLI 20–50%), and **non-adopters** (PLI < 20%). In **Salesforce**, create a report that flags prescribers whose PLI dropped by 10 points in a quarter — that’s a leading indicator of a **competitive win** or a **payer restriction**. For a $500M brand, a 5% improvement in PLI among the top 1,000 prescribers can add $25M in annual revenue. PLI is also a key input for **key account management** (KAM) programs.

```mermaid
flowchart TD
    A[Start: Select Pharma Revenue KPI] --> B{Primary Goal?}
    B -->|Cash Flow Visibility| C[Use NRx]
    B -->|Volume Growth| D[Use TRx]
    B -->|New Patient Adoption| E[Use NBRx]
    B -->|Profitability Analysis| F[Use GTN%]
    B -->|Sales Force Efficiency| G[Use RPR]
    C --> H[Pair with GTN% for Waterfall]
    D --> I[Pair with Market Share]
    E --> J[Pair with CAC per Prescriber]
    F --> K[Monitor Monthly vs. Contract Terms]
    G --> L[Benchmark vs. Industry Average]
    H --> M[Quarterly Finance Review]
    I --> N[Competitive Response Plan]
    J --> O[Launch Optimization]
    K --> P[PBM Contract Renegotiation]
    L --> Q[Territory Realignment]
```

## FAQ
**What is the difference between NRx and TRx?**  
NRx is net revenue per prescription (after rebates/discounts), while TRx is total prescription count. NRx measures cash flow; TRx measures volume. Both are needed for a complete picture.

**How often should GTN% be calculated?**  
Monthly, with a quarterly review against contract terms. A spike in GTN% often signals a PBM contract change or a Medicaid best-price adjustment.

**Which KPI is best for a product launch?**  
NBRx (new-to-brand prescriptions) is the leading indicator. Pair it with CAC per new prescriber to measure launch efficiency.

**Can I use these KPIs in a Salesforce dashboard?**  
Yes. All 10 can be built in **Salesforce Health Cloud** or **Veeva CRM** using custom report types and joined data from IQVIA or Symphony Health.

**What is a healthy PLI score?**  
For a market-leading brand, PLI above 50% among top prescribers is strong. For a challenger brand, 20–30% is acceptable in the first 12 months.

**How do I benchmark RPR?**  
IQVIA publishes annual sales force effectiveness benchmarks. A typical range is $2M–$8M per rep for primary care; specialty reps often exceed $10M.

**What tool automates NRx calculation?**  
**Model N** and **Accruent Revitas** automate NRx from contract terms. **Veeva Vault PromoMats** can centralize GTN data for reporting.

**Is CAC per prescriber applicable to generics?**  
Yes, but the range is much lower ($500–$2,000) due to lower margins and higher prescriber turnover.

**How does PDC affect payer contracts?**  
CMS uses PDC in Part D Star Ratings. A 5-point PDC improvement can lead to better formulary placement and higher NRx.

**Which KPI is most auditable by external auditors?**  
NRx and GTN% are directly tied to SEC 10-K disclosures and are audited by Big Four firms. TRx and NBRx are not typically audited.

## Sources
- [IQVIA National Sales Perspectives](https://www.iqvia.com/solutions/commercial-analytics/national-sales-perspectives)
- [Veeva CRM for Pharma](https://www.veeva.com/products/crm/)
- [Model N Revenue Management](https://www.modeln.com/solutions/revenue-management/)
- [Salesforce Health Cloud](https://www.salesforce.com/health/)
- [Gartner Sales Force Effectiveness Benchmarks](https://www.gartner.com/en/sales/insights/sales-force-effectiveness)
- [CMS Part D Star Ratings and PDC](https://www.cms.gov/medicare/health-plans/part-d-reporting-requirements)
- [ZS Associates Pharma Commercial Analytics](https://www.zs.com/industries/pharmaceuticals)
- [SEC 10-K Filing Guidance for Pharma](https://www.sec.gov/corpfin/pharmaceutical-biotechnology-industry-guide)

## Bottom Line
The top 10 pharmaceutical revenue KPIs — led by **Net Revenue per Prescription (NRx)** and anchored by **Prescriber Loyalty Index (PLI)** — form a complete commercial analytics stack for any RevOps team. Start with NRx and GTN% for financial accuracy, layer in TRx and NBRx for volume insights, and use RPR and PLI for sales-force optimization. Implement these in **Salesforce Health Cloud** or **Veeva CRM** with data feeds from **IQVIA** and **Model N** to build a real-time revenue operations dashboard that supports both quarterly reporting and daily decision-making.

*pharmaceutical revenue KPIs, pharma RevOps metrics, net revenue per prescription, GTN percentage, pharma sales analytics*

Was this helpful?

Related in the library